AnaptysBio Inc(ANAB) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor for generalized pustular psoriasis and palmoplantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd.; collaboration with Celgene Corporation; and immuno-oncology collaboration agreement with GlaxoSmithKline plc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.

Current Price

$24.38

RSI

49.404

Beta:

0.046182

February 25, 2021
342K
37.3M

2046.429 %
10530.556 %
265.866 %
82.968 %

$75,100,000
$6,959,000
$-1,652,000
$8,425,000
$16,684,000
$17,571,000
979.178 %
123.739 %
-609.988 %
-98.030 %
-5.316 %

$-19,931,000
$-97,488,000
$-61,848,000
$-30,070,000
$-4,259,000
$-5,266,000
389.127 %
-36.558 %
-51.381 %
-85.836 %
23.644 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.